Exosomal miR-23a and miR-192, Potential Diagnostic Biomarkers for Type 2 Diabetes
Abstract
Background Type 2 diabetes mellitus (T2D) is a common chronic disease, which lacks a specific diagnostic method. A substantial body of literature has demonstrated that the molecular constituents of extracellular vesicles (EVs) are promising as a novel biomarker for clinical diagnosis, especially exosomal miRNAs in biological fluids. Methods To find a diagnostic biomarker for T2D, we isolated exosomes from plasma and then quantitative PCR (qPCR) was used to detect the miRNA expression in plasma and exosomes from control subjects and T2D subjects. The ROC (receiver operating characteristic) curve and AUC (area under curve) were used to evaluate the diagnostic value of exosomal miRNAs. Results We found the exosomal levels of miR-23a and miR-192 were both significantly higher in T2D subjects. The AUC of miR-23a and miR-192 were 0.828 and 0.717, respectively. Further bioinformatics analysis was performed to speculate possible mechanisms. Conclusions In conclusion, exosomal miR-23a and miR-192 have good potential as diagnostic biomarkers for type 2 diabetes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Up-regulated expression of miR-23 has been observed in the plasma of patients with type 1 diabetes and type 2 diabetes mellitus.
“up-regulated expression of miR-23 has been witnessed in the plasma of patients with type 1 diabetes (T1DM) and type 2 diabetes mellitus (T2DM).”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [12]
In type 2 diabetic nephropathy patients (112 cases), miR-23-3p expression is decreased in serum, lower than both the control group and the simple diabetes group, and the decrease is more significant with increasing disease severity.
“the expression level of miR-23–3p was observed to be decreased in the serum of Type 2 diabetic nephropathy (T2DN) patients (totally 112 cases), with levels being lower than both the control group and the simple diabetes group. Furthermore, this decrease was more significant with increasing severity of the disease [12,16].”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [12]
Abnormal expression levels of miR-23 enable it to serve as a potential biomarker for diagnosis and progression of metabolic and immune disorders.
“To date, some studies have shown that abnormal expression levels of miR-23 enable it to serve as a potential biomarker for the diagnosis and progression of diseases such as metabolic and immune disorders [12,13].”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [12]
The citation lists haven’t been fetched yet
Cited by 9
- Authors
- Liu, C., Gao, Y., Wu, J., & Zou, J.
- Venue
- Clinical Laboratory
- Publisher
- Clinical Laboratory Publications
- Published
- 2021
- Volume
- 67
- Issue
- 02/2021
- ISSN
- 1433-6510 (ISSN-L)
- OpenAlex
- W3132536141
- Cited by
- 9
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Laboratory (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- type 2 diabetes, exosomal microRNAs, miR-23a, miR-192, diagnostic biomarkers, extracellular vesicles, plasma exosomes, microRNA expression
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, ROC Curve, Biomarkers, Tumor, Biomarkers, MicroRNAs, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
